Literature DB >> 23215730

Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients.

Yoshinao Muro1, Kazumitsu Sugiura, Masashi Akiyama.   

Abstract

BACKGROUND: The myositis-specific autoantibodies that characterize certain forms of inflammatory myopathy are useful in diagnosing dermatomyositis (DM) / polymyositis and predicting its prognosis. Autoantibodies to small ubiquitin-like modifier activating enzyme (SAE) have been identified as a DM-marker antibody in European Caucasians. OBJECTIVE AND METHODS: This study investigates the frequency and clinical characteristics of anti-SAE autoantibodies in Japanese patients with DM. Sera from 110 Japanese patients, including 13 with juvenile DM, were screened for anti-SAE antibodies by enzyme-linked immunosorbent assays. Positive sera were further examined by immunoblotting of the immunoprecipitates.
RESULTS: Only two patients (1.8%) were confirmed to have anti-SAE antibodies, and neither of these two patients had amyopathic or juvenile DM. One patient with anti-SAE had DM complicated with pulmonary arterial hypertension, and the other had cancer-associated DM. Both had hallmark cutaneous manifestations of DM.
CONCLUSION: This is the first report of anti-SAE antibodies from an Asian single center cohort. Although Japanese patients with anti-SAE antibodies have a clinical phenotype similar to that of Caucasian patients, their frequency was lower in the Japanese patients than in the previously reported Caucasian patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23215730     DOI: 10.3109/08916934.2012.755958

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  23 in total

1.  Antibodies to small ubiquitin-like modifier activating enzyme are associated with a diagnosis of dermatomyositis: results from an unselected cohort.

Authors:  Lisa K Peterson; Troy D Jaskowski; Sonia L La'ulu; Anne E Tebo
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

Review 2.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 3.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Authors:  Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.

Authors:  Sarah L Tansley; Neil J McHugh
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 5.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 6.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

7.  Myopathy should determine the anesthetic management in left ventricular hypertrabeculation/noncompaction.

Authors:  J Finsterer; C Stöllberger
Journal:  Heart Lung Vessel       Date:  2014

8.  The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.

Authors:  Qiu Xu; Qiu-Xiang Li; Fang-Fang Bi; Hui-Qian Duan; Yue-Bei Luo; Huan Yang
Journal:  Clin Rheumatol       Date:  2020-07-15       Impact factor: 2.980

Review 9.  The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Authors:  Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 10.  Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.

Authors:  Paige W Wolstencroft; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.